Andrew Hill Investment Advisors Inc. Acquires New Holdings in Globus Medical, Inc. $GMED

Key Points

• Andrew Hill Investment Advisors bought 41,288 shares of Globus Medical (NYSE:GMED) in Q4, a new stake valued at about $3.605 million that represents ~2.7% of the firm's holdings and is its 15th largest position.
• Globus beat quarterly expectations, reporting EPS of $1.28 vs. $1.06 estimated and revenue of $826.4M vs. $803.3M, with revenue up 25.7% year-over-year; the company has a market cap of ~$12.24B and a trailing P/E of ~22.97.
• The stock carries a consensus "Moderate Buy" from analysts with an average price target of $104.36, and ownership is heavily institutional—about 95.16% held by hedge funds and other institutional investors (insiders hold ~18.54%).

Andrew Hill Investment Advisors Inc. acquired a new stake in shares of Globus Medical, Inc. (NYSE:GMED - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 41,288 shares of the medical device company's stock, valued at approximately $3,605,000. Globus Medical accounts for approximately 2.7% of Andrew Hill Investment Advisors Inc.'s holdings, making the stock its 15th biggest holding.

Several other institutional investors also recently bought and sold shares of GMED. AQR Capital Management LLC increased its holdings in Globus Medical by 45.9% during the first quarter. AQR Capital Management LLC now owns 22,510 shares of the medical device company's stock valued at $1,622,000 after buying an additional 7,086 shares during the period. Integrated Wealth Concepts LLC grew its holdings in Globus Medical by 33.0% in the first quarter. Integrated Wealth Concepts LLC now owns 4,375 shares of the medical device company's stock worth $320,000 after purchasing an additional 1,085 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Globus Medical by 38.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,649 shares of the medical device company's stock worth $2,228,000 after purchasing an additional 8,540 shares during the last quarter. Jones Financial Companies Lllp grew its holdings in Globus Medical by 237.3% in the first quarter. Jones Financial Companies Lllp now owns 850 shares of the medical device company's stock worth $62,000 after purchasing an additional 598 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Globus Medical by 8.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,527 shares of the medical device company's stock worth $25,439,000 after purchasing an additional 28,027 shares during the last quarter. 95.16% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Royal Bank Of Canada lifted their price target on shares of Globus Medical from $92.00 to $100.00 and gave the stock an "outperform" rating in a report on Wednesday, December 17th. Wall Street Zen raised shares of Globus Medical from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 3rd. Needham & Company LLC lifted their price target on shares of Globus Medical from $112.00 to $114.00 and gave the stock a "buy" rating in a report on Wednesday, February 25th. TD Cowen raised shares of Globus Medical to a "strong-buy" rating in a report on Tuesday, January 27th. Finally, BTIG Research reaffirmed a "neutral" rating on shares of Globus Medical in a report on Tuesday, December 30th. Three investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $104.36.

Insider Buying and Selling at Globus Medical

In other news, EVP Kelly Huller sold 20,000 shares of the business's stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total transaction of $1,890,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 18.54% of the stock is owned by company insiders.

Globus Medical Price Performance

Shares of GMED opened at $90.51 on Monday. The firm has a market capitalization of $12.24 billion, a PE ratio of 22.97, a price-to-earnings-growth ratio of 2.11 and a beta of 1.09. Globus Medical, Inc. has a 1-year low of $51.79 and a 1-year high of $101.40. The company's fifty day moving average price is $88.68 and its 200-day moving average price is $82.56.

Globus Medical (NYSE:GMED - Get Free Report) last announced its quarterly earnings data on Tuesday, February 24th. The medical device company reported $1.28 earnings per share for the quarter, beating analysts' consensus estimates of $1.06 by $0.22. The firm had revenue of $826.42 million for the quarter, compared to analyst estimates of $803.29 million. Globus Medical had a net margin of 18.30% and a return on equity of 12.57%. The business's quarterly revenue was up 25.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.84 earnings per share. As a group, research analysts anticipate that Globus Medical, Inc. will post 3.44 EPS for the current fiscal year.

Globus Medical Profile

Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.

Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical, Inc. (NYSE:GMED - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.